News

Under the deal, Scribe Therapeutics and Biogen will develop and commercialise CRISPR-based therapies to treat amyotrophic lateral sclerosis (ALS). X-Editing (XE), which is Scribe’s first technology, is said

ET140203 follows on the experience gained from Eureka’s study of ET140202. ET140202 and ET140203 utilize Eureka’s proprietary ARTEMIS cell receptor platform engineered with a TCR-mimic antibody to target

“The FDA’s designation recognizes the morbidity and mortality burdens of sickle cell disease as well as its significant impact during childhood with life-long implications. With this designation, the

MyoKardia is engaged in the discovery and development of targeted therapies to treat serious cardiovascular diseases. As per terms of the merger deal, BMS subsidiary will begin a

FDA has provided the breakthrough therapy status based on data from the BPDCN cohort of the first-in-human study of IMGN632, said ImmunoGen. IMGN632 is a CD123-targeting ADC, which

This approval is based on a pre-specified interim analysis from the Phase 3 CheckMate -743 trial in which Opdivo + Yervoy (n=303) demonstrated superior overall survival (OS) versus

Farxiga is an oral, once-daily sodium-glucose co-transporter-2 inhibitor (SGLT2 inhibitor). Its breakthrough therapy designation in chronic kidney disease was driven by the findings of phase 3 DAPA-CKD trial.

The deal is valued at around $647m on an enterprise basis, including debt obligations expected to be assumed or repaid net of cash. As per terms of the

ILLUMINATE-B is now the seventh Phase 3 study of an RNAi therapeutic that has yielded positive results, and the first-ever study evaluating the safety and efficacy of this